CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Folotyn for Peripheral T-Cell Lymphoma

Project Number PC0138-000
Brand Name Folotyn
Generic Name Pralatrexate
Strength 20 mg/1 mL & 40 mg/2 mL
Tumour Type Lymphoma
Indication Peripheral T-Cell Lymphoma (PTCL)
Funding Request for the treatment of patients with relapsed or refractory PTCL
Review Status Complete
Pre Noc Submission Yes
NOC Date October 26, 2018
Manufacturer Servier Canada Inc.
Sponsor Servier Canada Inc.
Submission Date June 1, 2018
Submission Deemed Complete June 8, 2018
Submission Type Initial
Prioritization Requested Requested and Not Granted
Stakeholder Input Deadline ‡ June 15, 2018
Check-point meeting August 7, 2018
pERC Meeting January 17, 2019
Initial Recommendation Issued January 31, 2019
Feedback Deadline ‡ February 14, 2019
pERC Reconsideration Meeting March 21, 2019
Final Recommendation Issued April 4, 2019
Notification to Implement Issued April 22, 2019
Clarification The timeline of the review was temporarily stopped, pending receipt of the additional information. The timeline of the review has resumed as the additional information has now been provided.
Therapeutic Area Peripheral T-Cell Lymphoma (PTCL)
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.